Novavax (NVAX) Non-Current Deffered Revenue (2010 - 2026)

Novavax's Non-Current Deffered Revenue history runs 17 years deep, the most recent figure standing at $359.3 million for Q1 2026.

• On a quarterly basis, Non-Current Deffered Revenue fell 12.28% year-over-year to $359.3 million in Q1 2026; TTM through Mar 2026 was $359.3 million, a 12.28% decrease from a year earlier, with the FY2025 full-year figure at $358.9 million, down 19.67% from the prior year.
• Non-Current Deffered Revenue steadied at $359.3 million in Q1 2026 per NVAX's latest filing, from $358.9 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $1.0 billion in Q3 2022 and bottomed at $179.4 million in Q4 2022.
• The 5-year median for Non-Current Deffered Revenue is $446.8 million (2024), against an average of $518.2 million.
• Across the five-year window, Non-Current Deffered Revenue soared 246.8% in 2023 and plunged 51.33% in 2025, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $179.4 million in 2022, then surged by 246.8% to $622.2 million in 2023, then fell by 28.19% to $446.8 million in 2024, then dropped by 19.67% to $358.9 million in 2025, then advanced by 0.09% to $359.3 million in 2026.
• Per Business Quant, the three latest NVAX Non-Current Deffered Revenue figures stand at $359.3 million (Q1 2026), $358.9 million (Q4 2025), and $397.1 million (Q3 2025).